“Quality by Design Approaches in Intranasal Drug Delivery Systems: Current Progress, Challenges and Future Perspectives”
Abstract
Intranasal drug delivery has emerged as a highly promising administration route owing to its unique anatomical advantages rich vascularization, large mucosal surface area (~150–180 cm²), and direct olfactory/trigeminal access to the central nervous system (CNS) bypassing the blood-brain barrier (BBB). Despite these advantages, mucociliary clearance, limited nasal volume (~20 mL per nostril), enzymatic barriers, and inter-individual physiological variability complicate reproducible formulation development. Quality by Design (QbD), a science-and risk-based pharmaceutical development framework endorsed by ICH Q8, Q9, and Q10, provides a structured, systematic approach to address these challenges. This review comprehensively examines QbD applications across intranasal dosage forms including nasal solutions, sprays, powders, mucoadhesive systems, thermosensitive in situ gels, nanoemulsions, polymeric nanoparticles, and lipid nanoparticles (SLN/NLC). Key QbD elements—Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), Design Space, and Control Strategy— are systematically discussed. Risk assessment tools (Ishikawa diagrams, FMEA, Pareto analysis) and Design of Experiments (DoE) strategies including Plackett-Burman, Box-Behnken, and Central Composite Designs with Response Surface Methodology are elaborated. Special emphasis is given to nose-to-brain delivery for CNS disorders (Alzheimer's, Parkinson's, epilepsy, migraine) with supporting case studies. Regulatory expectations (FDA, EMA) and emerging trends including AI-assisted development, digital twins, continuous manufacturing, and personalized medicine are also addressed. QbD is confirmed as essential to ensure strong, consistent, and compliant intranasal drug products.